Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content

Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
82 hot topic(s) found with the query "Statins "

Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky James et al. JAMA 2020 Feb (7) 646-655 (Posted: Feb-20-2020 9AM)


The Stroke Family
The FH Foundation, January 6, 2020 (Posted: Jan-07-2020 8AM)

When some people are first diagnosed with FH, they have a hard time believing that they must be on medication to ensure protection of their arteries. There are folks coming to FH groups in disbelief, asking “if I don’t take my statins, or some other therapy, will I really get a heart attack? Will I be young when these things might happen to me?”


Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities.
Vuorio A et al. Journal of internal medicine 2020 Jan 287(1) 2-18 (Posted: Jan-02-2020 9AM)

The cumulative burden of two genetically determined pro-atherogenic lipoproteins, LDL and Lp(a), is a potent driver of ASCVD in HeFH patients. Statins are the cornerstone of treatment of HeFH, but they do not lower the plasma concentrations of Lp(a). Emerging therapies effectively lower Lp(a) target the transcriptional product of the LPA gene.


Genetic contribution to lipid target achievement with statin therapy: a prospective study.
Ruiz-Iruela Cristina et al. The pharmacogenomics journal 2019 Dec (Posted: Dec-10-2019 8AM)

Statin therapy response is highly variable. Variants of lipid metabolism genes and statin pharmacokinetic modulators could play a role, however, the impact of most of these variants remains unconfirmed. A prospective and multicenter study included 252 patients was carried out in order to assess the impact of gene variants on statin response.


Many Adults with Familial Hypercholesterolemia Are Not Meeting Goal LDL-Cholesterol Level
RF Green et al, CDC Blog Post, November 15, 2019 Brand (Posted: Nov-15-2019 0PM)

Among patients in the CASCADE FH registry, 73.7% were on statins, Even among the study population, which was selected from specialty clinics and likely receiving more aggressive cholesterol-lowering therapies than the general FH population, only 48% achieved LDL-cholesterol <100 mg/dL, and only 22% reached LDL-cholesterol <70 mg/dL.


Making the Case for Early Statins in Familial Hypercholesterolemia
P Wendling, Medscape, October 16, 2019 (Posted: Oct-18-2019 8AM)

Starting statin therapy during childhood in patients with familial hypercholesterolemia has beneficial effects on atherosclerotic progression. The cumulative incidence of cardiovascular events at age 39 years was 1% among patients with FH who began taking statins during childhood, compared with 26% among their affected parents.


20-Year Follow-up of Statins in Children with Familial Hypercholesterolemia
IK Luirink et al, NEJM, October 17, 2019 (Posted: Oct-17-2019 9AM)

In this study, initiation of statin therapy during childhood in patients with familial hypercholesterolemia slowed the progression of carotid intima–media thickness and reduced the risk of cardiovascular disease in adulthood.


How to implement clinical guidelines to optimise familial hypercholesterolaemia diagnosis and treatment.
Farnier Michel et al. Atherosclerosis. Supplements 2017 Apr 2625-35 (Posted: Oct-09-2019 8AM)


Low-density lipoprotein cholesterol goal achievement in patients with familial hypercholesterolemia in countries outside Western Europe: The International ChoLesterol management Practice Study.
Blom Dirk J et al. Journal of clinical lipidology (4) 594-600 (Posted: Sep-13-2019 9AM)

Data from an international practice survey of familial hypercholesterolemia: 1) low cholesterol goal attainment (32%); 2) statin doses were often inadequate, and 3) cholesterol absorption inhibitor use was low.


Genetics, Dyslipidemia, and Cardiovascular Disease: New Insights.
Stein Ricardo et al. Current cardiology reports 2019 Jun (8) 68 (Posted: Jun-27-2019 8AM)

In the last two decades, significant advances have been made in understanding the genetic basis of dyslipidemias. This review discusses current knowledge of the genetics and pathophysiology of disorders that predispose to dyslipidemia. The authors also discuss new cholesterol-lowering medications, including PCSK9 inhibitors.


2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline.
Grundy Scott M et al. Annals of internal medicine 2019 May (Posted: May-31-2019 10AM)


Mendelian Randomization Study of ACLY and Cardiovascular Disease.
Ference Brian A et al. The New England journal of medicine 2019 Mar (11) 1033-1042 (Posted: Mar-14-2019 11AM)


The role of statins in the treatment of familial hypercholesterolemia
S Gilding, The FH Foundation, March 5, 2019 (Posted: Mar-06-2019 8AM)


Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018.
Brunham Liam R et al. The Canadian journal of cardiology 2018 Dec 34(12) 1553-1563 (Posted: Dec-19-2018 10AM)


Role of PCSK9 inhibitors in high risk patients with dyslipidemia: Focus on familial hypercholesterolemia.
Papademetriou Vasilios et al. Current pharmaceutical design 2018 Oct (Posted: Oct-17-2018 10AM)


New horizons in the pathogenesis, pathophysiology and treatment of familial hypercholesterolaemia.
Viigimaa Margus et al. Current pharmaceutical design 2018 Oct (Posted: Oct-17-2018 8AM)


Value of a Hypothetical Pharmacogenomic Test for the Diagnosis of Statin-Induced Myopathy in Patients at High Cardiovascular Risk.
Mitchell Dominic et al. Molecular diagnosis & therapy 2018 Sep (Posted: Sep-19-2018 9AM)


Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Streja Elani et al. Seminars in nephrology 2018 Jul 38(4) 369-382 (Posted: Aug-08-2018 9AM)


Lipids and Women's Health: Recent Updates and Implications for Practice.
Fay Kathryn E et al. Journal of women's health (2002) 2018 Jul (Posted: Jul-18-2018 9AM)


MicroRNAs and response to statins in patients with hypercholesterolemia: from basic research to precision medicine.
Zambrano Tomás et al. Pharmacogenomics 2018 May (Posted: May-23-2018 9AM)


Improving identification and management of familial hypercholesterolaemia in primary care: Pre- and post-intervention study.
Weng Stephen et al. Atherosclerosis 2018 Apr 27454-60 (Posted: May-16-2018 9AM)


Cardiovascular Genetic Risk Testing for Targeting Statin Therapy in the Primary Prevention of Atherosclerotic Cardiovascular Disease: A Cost-Effectiveness Analysis.
Jarmul Jamie et al. Circulation. Cardiovascular quality and outcomes 2018 Apr 11(4) e004171 (Posted: Apr-18-2018 10AM)


A Discrete Event Simulation Model to Assess the Economic Value of a Hypothetical Pharmacogenomics Test for Statin-Induced Myopathy in Patients Initiating a Statin in Secondary Cardiovascular Prevention.
Mitchell Dominic et al. Molecular diagnosis & therapy 2018 Apr (Posted: Apr-18-2018 10AM)


Safety of statin treatment in children with familial hypercholesterolemia: Filling the gaps.
Rocha Viviane Z et al. Journal of clinical lipidology 2017 Dec (Posted: Jan-11-2018 6PM)


How close are we to implementing a genetic risk score for coronary heart disease?
Beaney Katherine et al. Expert review of molecular diagnostics 2017 Oct (10) 905-915 (Posted: Dec-31-2017 8AM)


Detection of familial hypercholesterolemia in patients from a general practice database.
Casula Manuela et al. Atherosclerosis. Supplements 2017 Oct 2925-30 (Posted: Oct-04-2017 11AM)


Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk
BA Ference, et al. JAMA, August 28, 2017 (Posted: Aug-28-2017 1PM)


Cholesterol Management in the Era of PCSK9 Inhibitors.
Svatikova Anna et al. Current cardiology reports 2017 Sep (9) 83 (Posted: Aug-18-2017 9AM)


PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity-Reply.
Koren Michael J et al. JAMA cardiology 2017 Aug (Posted: Aug-18-2017 8AM)


PCSK9 Inhibitors, Statins, Low-Density Lipoprotein Cholesterol, Mevalonate Pathway, and Toxicity.
Guijarro Carlos et al. JAMA cardiology 2017 Aug (Posted: Aug-18-2017 8AM)


How Studying Familial Hypercholesterolemia Resulted in the Discovery of Statins as an Effective Treatment for High Cholesterol
JAMA Podcast, July 25, 2017 (Posted: Jul-26-2017 8AM)


Impact of Pharmacogenetics on Efficacy and Safety of Statin Therapy for Dyslipidemia.
Maxwell Whitney D et al. Pharmacotherapy 2017 Jul (Posted: Jul-11-2017 10AM)


Statins for children with inherited high blood cholesterol
VA Kuoppola et al, Cochrane reviews, July 7, 2017 (Posted: Jul-07-2017 3PM)


The Effect of Genetic Polymorphisms in SLCO2B1 on the Lipid-lowering Efficacy of Rosuvastatin in Healthy Adults with Elevated Low-density Lipoprotein.
Kim Tae-Eun et al. Basic & clinical pharmacology & toxicology 2017 Jun (Posted: Jun-21-2017 8AM)


When do paediatric patients with familial hypercholesterolemia need statin therapy?
Hennig Matylda et al. Developmental period medicine 2017 21(1) 43-50 (Posted: May-31-2017 11AM)


Polygenic Risk Score Identifies Subgroup with Higher Burden of Atherosclerosis and Greater Relative Benefit from Statin Therapy in the Primary Prevention Setting.
Natarajan Pradeep et al. Circulation 2017 Feb (Posted: May-30-2017 8PM)


How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
Masana Luis et al. Atherosclerosis 2017 May 262107-112 (Posted: May-24-2017 9AM)


PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt Amand F et al. The Cochrane database of systematic reviews 2017 Apr CD011748 (Posted: May-20-2017 10AM)


Younger Adults With Severe Dyslipidemia Less Likely to Be Prescribed Statins
TCTMD, January 5, 2017 (Posted: Jan-06-2017 7AM)


Statins for Prevention of Cardiovascular Disease in Adults Evidence Report and Systematic Review for the US Preventive Services Task Force
R Chou et al, JAMA, November 15, 2016 (Posted: Nov-14-2016 6PM)


Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering
Fatima Rodriguez, et al, JAMA, November 15, 2016 (Posted: Nov-14-2016 6PM)


Statin Use for the Primary Prevention of Cardiovascular Disease in Adults US Preventive Services Task Force Recommendation Statement
USPSTF, JAMA, November 15, 2016 (Posted: Nov-13-2016 2PM)


Economic Evaluation of a Pharmacogenomics Test for Statin-Induced Myopathy in Cardiovascular High-Risk Patients Initiating a Statin.
Mitchell Dominic et al. Molecular diagnosis & therapy 2016 Oct (Posted: Nov-02-2016 10AM)


Familial hypercholesterolemia in a large ambulatory population: Statin use, optimal treatment, and identification for advanced medical therapies.
Knickelbine Thomas et al. Journal of clinical lipidology 10(5) 1182-7 (Posted: Oct-05-2016 2PM)


Meta-analysis of genome-wide association studies of HDL cholesterol response to statins.
Postmus Iris et al. Journal of medical genetics 2016 Sep (Posted: Sep-04-2016 9PM)


Statins in Heterozygous Familial Hypercholesterolemia
American College of Cardiology Foundation, July 11, 2016 (Posted: Jul-12-2016 7AM)


My Approach to the Patient With Familial Hypercholesterolemia.
Safarova Maya S et al. Mayo Clinic proceedings 2016 Jun 91(6) 770-86 (Posted: Jun-08-2016 10AM)


Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins.
Rallidis Loukianos S et al. Atherosclerosis 2016 Mar 24917-21 (Posted: Apr-13-2016 11AM)


Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia.
Besseling Joost et al. European heart journal 2016 Apr (Posted: Apr-06-2016 9AM)


Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up.
Perez de Isla Leopoldo et al. Journal of the American College of Cardiology 2016 Mar (11) 1278-85 (Posted: Apr-02-2016 9AM)


The UK Paediatric Familial Hypercholesterolaemia Register: preliminary data.
Ramaswami Uma et al. Archives of disease in childhood 2016 Mar (Posted: Mar-09-2016 9AM)


Seventeen years of statin pharmacogenetics: a systematic review.
Leusink Maarten et al. Pharmacogenomics 2016 Jan (2) 163-80 (Posted: Feb-22-2016 0PM)


Statin-Associated Autoimmune Myopathy
AL Mammen. NEJM, February 18, 2016 (Posted: Feb-22-2016 0PM)


Management of Familial Hypercholesterolemia in Hong Kong.
Hu Miao et al. Journal of atherosclerosis and thrombosis 2016 Feb (Posted: Feb-17-2016 0PM)


Familial hypercholesterolemia: Review of diagnosis, screening, and treatment.
Turgeon Ricky D et al. Canadian family physician Me´decin de famille canadien 2016 Jan (1) 32-7 (Posted: Jan-27-2016 10AM)


KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Pharmacological Management.
Mallett Andrew et al. Seminars in nephrology 2015 Nov (6) 582-589.e17 (Posted: Jan-06-2016 5PM)


Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes.
Thompson Gilbert R et al. Atherosclerosis 2015 Nov (1) 328-33 (Posted: Dec-19-2015 10AM)


Optimal Treatment using Statins from Childhood in Heterozygous Familial Hypercholesterolemia.
Nohara Atsushi et al. J. Atheroscler. Thromb. 2015 Sep 15. (Posted: Sep-16-2015 3PM)


Temporal trends in lipid screening and therapy among youth from 2002 to 2012.
Zachariah Justin P et al. J Clin Lipidol 2015 Sep-Oct (5 Suppl) S77-87 (Posted: Sep-13-2015 1PM)


Identification and treatment of patients with homozygous familial hypercholesterolaemia: information and recommendations from a Middle East advisory panel.
Al-Ashwal Abdullah et al. Curr Vasc Pharmacol 2015 Aug 27. (Posted: Sep-02-2015 0PM)


Cardiovascular pharmacogenomics: current status and future directions.
Roden Dan M et al. J. Hum. Genet. 2015 Jul 16. (Posted: Sep-01-2015 2PM)


How Well Do Customers of Direct-to-Consumer Personal Genomic Testing Services Comprehend Genetic Test Results? Findings from the Impact of Personal Genomics Study.
Ostergren Jenny E et al. Public Health Genomics 2015 Jun 16. (Posted: Sep-01-2015 11AM)


Cascade screening of familial hypercholesterolemia must go on.
Galema-Boers J M H et al. Atherosclerosis 2015 Jul 11. 242(2) 415-417 (Posted: Aug-19-2015 0PM)


Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association.
Fox Caroline S et al. Circulation 2015 May 12. 131(19) 1715-36 (Posted: Jul-29-2015 10AM)


Prevention of hepatocellular carcinoma by correction of metabolic abnormalities: Role of statins and metformin.
Ampuero Javier et al. World J Hepatol 2015 May 18. (8) 1105-11 (Posted: Jun-10-2015 11AM)


Emerging PCSK9 inhibitors for treating dyslipidaemia: buttressing the gaps in coronary prevention.
Page Michael M et al. Expert Opin Emerg Drugs 2015 Apr 10. 1-14 (Posted: Apr-29-2015 7PM)


Efficacy and Safety of Pitavastatin in Japanese Male Children with Familial Hypercholesterolemia.
Harada-Shiba Mariko et al. J. Atheroscler. Thromb. 2015 Apr 20. (Posted: Apr-29-2015 7PM)


NIH Research Matters: Genetics Help Predict Heart Disease Risk, Statin Benefits
Brand (Posted: Mar-23-2015 2PM)


Statins work for those at highest risk of heart attack - study,
the Guardian, March 3, 2015 (Posted: Mar-04-2015 9AM)


Statin myotoxicity: a review of genetic susceptibility factors.
Needham M et al. Neuromuscul. Disord. 2014 Jan (1) 4-15 (Posted: Mar-04-2015 5AM)


Genetics and personalized medicine--a role in statin therapy?
Patel Jaideep et al. Curr Atheroscler Rep 2014 Jan (1) 384 (Posted: Mar-04-2015 5AM)


Cardiovascular pharmacogenomics: expectations and practical benefits.
Turner R M et al. Clin. Pharmacol. Ther. 2014 Mar (3) 281-93 (Posted: Mar-04-2015 5AM)


Pharmacogenomics, lipid disorders, and treatment options.
Gryn S E et al. Clin. Pharmacol. Ther. 2014 Jul (1) 36-47 (Posted: Mar-04-2015 5AM)


The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Ramsey L B et al. Clin. Pharmacol. Ther. 2014 Oct (4) 423-8 (Posted: Mar-04-2015 5AM)


No association between CYP3A4*22 and statin effectiveness in reducing the risk for myocardial infarction.
Leusink Maarten et al. Pharmacogenomics 2014 Aug (11) 1471-7 (Posted: Mar-04-2015 5AM)


Prediction of LDL cholesterol response to statin using transcriptomic and genetic variation.
Kim Kyungpil et al. Genome Biol. 2014 (9) 460 (Posted: Mar-04-2015 5AM)


Pharmacogenetics and Statin Treatment: Reality or Theory?
Bousoula E et al. Curr Vasc Pharmacol 2015 Jan 30. (Posted: Mar-04-2015 5AM)


What are we able to achieve today for our patients with homozygous familial hypercholesterolaemia, and what are the unmet needs?
Santos Raul D et al. Atheroscler Suppl 2014 Sep (2) 19-25 (Posted: Feb-28-2015 0PM)


Normalization of low-density lipoprotein receptor expression in receptor defective homozygous familial hypercholesterolemia by inhibition of PCSK9 with alirocumab.
Lambert Gilles et al. J. Am. Coll. Cardiol. 2014 Dec 2. (21) 2299-300 (Posted: Feb-28-2015 0PM)


Pharmacological treatment of a Sardinian patient affected by Autosomal Recessive Hypercholesterolemia (ARH).
Muntoni Sandro et al. J Clin Lipidol 0 (1) 103-6 (Posted: Feb-28-2015 0PM)


Ezetimibe: Rescued by Randomization (Clinical and Mendelian).
McPherson Ruth et al. Arterioscler. Thromb. Vasc. Biol. 2014 Dec 30. (Posted: Feb-16-2015 9AM)


High Blood Cholesterol
From NHLBI health topic site Brand (Posted: Jan-01-2014 0AM)

Also known as Hypercholesterolemia High blood cholesterol is a condition that causes the levels of certain bad fats, or lipids, to be too high in the blood. This condition is usually caused by lifestyle factors, such as diet, in combination with the genes that you inherit from your parents. Less commonly, it is caused by other medical conditions or some medicines. You may be diagnosed with high blood cholesterol if you consistently have high levels of bad cholesterol in your blood in a routine test called a lipid panel. To treat high blood cholesterol, your doctor may recommend heart-healthy lifestyle changes, such as heart-healthy eating, quitting smoking, or aiming for a healthy weight. Your doctor may also prescribe medicines, such as statins, to lower and control your high blood cholesterol. Untreated high blood cholesterol can lead to the buildup of plaque in the blood vessels, called atherosclerosis. Plaque buildup increases your risk for heart attack, stroke, and peripheral artery disease. Explore this Health Topic to learn more about high blood cholesterol, NHLBI?s role in research and clinical trials to improve health, and where to find more information.



Disclaimer: Articles listed in Hot Topics of the Day are selected by the CDC Office of Public Health Genomics to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP